. On 23 November, 2009, Simcere urged the plank of Jiangsu Yanshen to displace its general head and manager of quality assurance. Jiangsu Yanshen subsequently decided to implement a total suspension of production to be able to improve its quality control systems effective on November 30, 2009. Related StoriesNew initiative released to accelerate seek out effective HIV vaccineNew vaccine applicant shows great guarantee at fighting respiratory syncytial virusNew vaccine appears to be far better in reducing 'bad' LDL cholesterolThe SFDA issued a public see on December 3, 2009 announcing the initiation of a thorough investigation into quality problems with respect to human use rabies vaccine produced by two companies including Jiangsu Yanshen.Total data will be offered following the completion of the study. ‘The observed PFS for AGS-003 plus sunitinib is encouraging in this unfavorable prognosis group of individuals,’ stated Robert A. Figlin, M.D., of Cedars-Sinai’s Samuel Oschin In depth Cancer Institute and lead author. ‘Further research of this combination in a randomized setting versus sunitinib only is warranted to verify these promising results. An interview with Dr Matt SilverJumping genes: a marker for early cancer medical diagnosis? An interview with Dr KazazianNovartis announces FDA acceptance of Odomzo 200 mg capsules for treatment of laBCC patientsTwenty-five sufferers with newly diagnosed, obvious cell mRCC were signed up for the scholarly study, of which 22 received at least one dose of AGS-003.